^
    Back
    Association details:
    Biomarker:POU2F3 overexpression
    Cancer:Small Cell Lung Cancer
    Drug:Zepzelca (lurbinectedin) (Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2023
    Title:

    Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response

    Published date:
    03/15/2023
    Excerpt:
    Lurbinectedin is highly effective in all molecular subtypes of SCLC in vitro and in vivo, with IC50 values at least two logs more potent than for other antitumoral agents and its activity is even greater in tumors with high POU2F3 expression and/or high SLFN11 expression.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Thorac Cancer
    Title:

    High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin

    Published date:
    03/12/2022
    Excerpt:
    mRNA expression of POU2F3 was weakly correlated with the drug sensitivity of etoposide (rho = −0.7381, p = 0.0458) and strongly associated with the drug sensitivity of lurbinectedin (rho = −0.9286, p = 0.0022) 
    DOI:
    https://doi.org/10.1111/1759-7714.14382